

1 **Title**

2 **Cytogenetic & Molecular analysis in Premature Ovarian Failure**

3 Chetan sahni¹, Rima dada²

4 1. Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

5 2. All India Institute of Medical Sciences, New Delhi, India

6 First Author: Dr. CHETAN SAHNI, Assistant Professor, IMS-BHU, chetansahni@bhu.ac.in

7 Corresponding Author: Dr. Rima Dada, Professor, AIIMS NEW DELHI,
8 rima_dada@rediffmail.com

9

10 **ABSTRACT:**

11 **Introduction:** Premature Ovarian Failure (POF) being a heterogeneous genetic disease involves the
12 interaction of multiple genetic defects and environmental factors and has been associated with
13 several chromosomal abnormalities, single gene mutations, and genetic polymorphisms. BMP15 is a
14 member of the transforming growth factor β (TGF- β) family. BMP15 gene product (protein) have 3
15 domains, mature domain (c-terminal region) of BMP15 binds to receptors located on granulosa cell
16 surface to participate in key steps regarding ovarian function, such as granulosa cell proliferation
17 and follicle maturation, ovulation rate modulation, oocyte competence determination and regulating
18 granulosa cell sensitivity to FSH. Single nucleotide polymorphisms (SNPs) of the BMP-15 gene are
19 associated with POF.

20 **Materials & Methods:** 30 POF patients and 30 healthy age matched controls were recruited for
21 cytogenetic and molecular analysis. 10 ml whole blood was collected for karyotyping and PCR and
22 PCR was performed for known SNPs of BMP-15 gene (-9C>G, 538G>A, 788insTCT and 852C>T)
23 respectively. Amplified PCR products were sequenced commercially.

24

25 **Observation/Result:** Thirty cases (mean age 30 years) and thirty healthy controls (mean age 23
26 years) were recruited for the study. On cytogenetic analysis 2 cases had a 45, XO chromosomal
27 complement. One case was heterozygous for the SNP (-9C>G) and one control was homozygous for
28 the same SNP.

29

30 **Discussion:** The prevalence of this SNP was about 10.7% in cases & 3.3% in healthy controls. This
31 polymorphism in promoter region may cause altered expression of the gene and results in POF.

32

INTRODUCTION

33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

[Type text]

34 Premature ovarian failure (POF) refers to the development of amenorrhea due to cessation of
35 ovarian function before the age of 40 years and is characterized by low estrogen and elevated
36 serum gonadotropin. Elevated levels of Follicle Stimulating hormone (FSH) (≥ 40 mIU/ml)
37 detected on at least two occasions a few weeks apart, is indicative of premature ovarian
38 failure.^{1,2} The triad for the diagnosis of POF is amenorrhea, hypergonadotropism, and
39 hypoestrogenism. POF affects approximately 1% of the female population by age of 40 years
40 and 0.1% by age of 30 years worldwide.³ POF is not the same as natural menopause, as natural
41 menopause is an irreversible condition, while POF is characterized by intermittent ovarian
42 function in one half of young women.⁴

43 In the patients of POF, Hypoestrogenism can be satisfactorily treated by hormone
44 replacement therapy. In contrast, fertility cannot be recovered when the diagnosis of POF (or
45 end-stage POI- premature ovarian insufficiency) is generally reached and is often compromised
46 in the early phases of the disease when the clinical manifestations are absent.⁵ The age of onset
47 varies widely, depending on the age of onset, the disorder can manifest as primary amenorrhea,
48 without menarche, or secondary amenorrhea after the pubertal development.⁶

49 Kinch et al., (1965) found that there are two histopathological types of POF,
50 a follicular, and follicular form. In the a follicular form, there is a total depletion of ovarian
51 follicles with permanent loss of ovarian function. In the follicular form, follicular structures are
52 still preserved, hence a possibility of either spontaneous or induced return of ovarian function
53 exists.⁷

54

55

56 **Causes of Ovarian Failure**

[Type text]

57 The causes of premature ovarian failure broadly categorized into the genetic and pathological
58 category.¹ Amongst the genetic causes numerical & structural anomalies of the X chromosome
59 adversely affect ovarian function. The most common form of X chromosome defect is Turner's
60 syndrome. Besides genetic causes, a wide spectrum of pathogenic mechanisms like autoimmune,
61 metabolic (galactosemia), infections (mumps), iatrogenic (anti-cancer treatment) may lead to the
62 development of POF. But, the Genetic causes of POF probably comprise about one-third to one-half
63 of all cases.⁸

64 **Genetic Causes**

65 Chromosomal defects involving the X-chromosome are frequently seen in women with POF. The
66 deletion of X chromosome makes follicle or ovum unstable.¹ In the majority of cases, X
67 chromosome defects cause deletion or disruption of genes located in the critical region of the X
68 chromosome between Xq13 and Xq26, which are critical for ovarian function. Several genes
69 responsible for oogenesis and normal ovarian functions are present on the X chromosome and
70 autosomes.

71 **Genes Involved**

72 Many genes on the X chromosome and autosomes regulate ovarian function. In a meta-analysis, D.
73 Pu et.al reported that five genes *BMP15*, *ESR1*, *FMRI*, *FSHR*, and *INH* are very important for
74 normal ovarian functions. They also found that single nucleotide polymorphisms and mutations in
75 these genes were found to be significantly more common in patients with POF compared with
76 controls.⁹

77

78 **BMP 15 Gene**

79 In our study, we had evaluated the polymorphism in the *BMP15* gene, as the *BMP15* gene has a very
80 important role in ovarian functions. The *BMP15* is a member of the transforming growth factor β
81 (TGF- β) family, which is expressed by oocytes from the early stages of follicular maturation and
82 during all stages of development.¹⁰ BMP15 protein can form homodimers (BMP15: BMP15) or
83 heterodimers (BMP15: GDF9). The secreted soluble dimer binds to receptors located on the
84 granulosa cell surface to participate in key steps regarding ovarian function, such as granulosa cell
85 proliferation and follicle maturation, ovulation rate modulation, oocyte competence determination
86 and regulating granulosa cell sensitivity to FSH.¹¹

87 In the Sanger sequencing projects of the *BMP15* encoding region in panels of POF patients, more
88 than 15 missense variants were identified.¹² Most of them were located in the protein pro-region.
89 This scenario led to engage the researchers in a recent functional exploration of whether *BMP15*
90 promoter polymorphism might be related to the POF phenotype. It has been also established that this
91 variant modifies the paired-like homeodomain transcription factor 1 (PITX1) binding site and leads
92 to *BMP15* promoter transactivation disturbances.¹³ This might suggest that fine-tuning of *BMP15*
93 expression is critical for normal human ovarian physiology.

94 *BMP15* gene located on the short arm of the X chromosome (Xp11.2) within a 'POF
95 critical region'.¹⁴ *BMP15* gene has two exons of 328 bp and 851 bp. In humans, mutations in the
96 *BMP15* gene have been found in association with both primary amenorrhea and secondary
97 amenorrhea in several worldwide POF cohorts with a variable prevalence between 1.5 and 12%.⁵

98

99

100

101 In light of these findings, one could hypothesize that *BMP15* variations might play a predisposing
102 role in POF. The functional mechanism by which *BMP15* variants with a proven biological impact
103 may disturb ovarian folliculogenesis is presently unknown. It may be predicted that a diminished
104 *BMP15* paracrine signal in the follicle would involve an impairment of the anti-apoptotic effects on
105 granulosa cells.⁵ Indeed, further studies are needed to understand the exact role of *BMP15* variants in
106 POF pathogenesis. Thus in our study, we have evaluated the cytogenetic and molecular basis
107 (mutation in *BMP15*) of disease in cases of premature ovarian failure.

108

109

110

Materials and Methods

111

112 The study population consisted of 30 females of POF with no identifiable etiology after detailed
113 clinical, gynecological evaluation. The control group included 30 healthy females with normal
114 menstrual and fertility history. The relevant information regarding physical examination, clinical
115 investigations, developmental milestones, occupational or environmental exposure to heat, radiation,
116 chemicals, or toxins, were documented in a pre-designed proforma. Written informed consent was
117 taken from each patient and control. The study was approved by the Institute Ethical Committee-
118 A.I.I.M.S. New Delhi (ref-no. IESC/T-150/01.04.2015).

119

120 **The Inclusion criteria for study (infertile) group were:** only Cases of idiopathic POF with
121 primary and secondary amenorrhea after detailed gynecological & cytogenetic investigations, with
122 no recent history of illness, fever or medication (in past three months).

123

124

125

[Type text]

126 **The Inclusion criteria for Controls (fertile) group were:** Controls who had normal menstrual
127 and fertility history, with no recent history of illness, fever, or medication (in the past three
128 months).

129

130 **The Exclusion criteria for the study group and control group:** 1) Gross dysmorphic
131 abnormalities, structural defects, and systemic infection of the urogenital/reproductive system. 2)
132 History of surgical intervention or trauma of genital/reproductive tract obstruction. 3) History of
133 miscarriage, abortion whether spontaneous or induced. 4) Syndromic cases as Turner and Klinefelter
134 (on cytogenetic evaluation).

135

136 For this case-control study, 30 cases of mean age 23 ± 4.15 years were recruited from the
137 Department of Obstetrics & Gynecology, AIIMS, New Delhi, and 30 controls of mean age 25 ± 3.49
138 years were recruited from a group of healthy wives of cases with male factor infertility & healthy
139 female volunteers from AIIMS, New Delhi. Cases included in this study were presented with
140 premature ovarian failure but on clinical examination, no obvious cause was determined in them and
141 all cases were phenotypically normal. So these cases were found idiopathic and further cytogenetic
142 (karyotyping) and molecular (PCR) analyses were needed in all these cases, While Controls were
143 presented with normal menstrual and fertility history, so cytogenetic (karyotyping) analysis was not
144 done in controls. Three genetic analyses were used to observe the result.

145

- 146 1. Cytogenetic (Karyotyping) analysis in Cases (infertile group)
- 147 2. Molecular (PCR) analysis in both Cases (infertile group) & Controls (healthy fertile group)

148

149

150 **1. Cytogenetic analysis**

[Type text]

151 In all infertile cases, the chromosomal analysis was done to identify any numerical or structural
152 chromosomal aberration. The metaphases were captured under 100X (Olympus optical company,
153 Ltd., Tokyo, Japan). The captured metaphases were analyzed using image analysis software
154 Cytovision 3.7 provided by Applied Imaging (ZEISS microscope, Germany) and classified
155 according to ISCN 2005. At least 50 metaphases were analyzed and karyotyped for each individual.

156

157 In karyotyping, it was observed that two cases out of 30 presented with Turner's karyotype
158 (45, X0). Although, in these two cases Turner's karyotype (45, X0) was observed but they were
159 phenotypically normal. (fig. 1) These two cases were excluded from the study as cytogenetically
160 normal, idiopathic cases were included in this study. The remaining 28 cases were cytogenetically
161 normal.

162

163

164 **2. Molecular (PCR) analysis**

165 SNPs of the *BMP15* gene were observed by using molecular (PCR) analysis. This molecular analysis
166 was done in 28 cases which were found clinically as well as cytogenetically normal but have the
167 phenotype of premature ovarian failure and in 30 healthy fertile controls. Total Genomic DNA was
168 extracted from peripheral blood. Blood samples were collected from cases and controls in EDTA
169 vials only after informed consent. DNA was isolated from 58 (28 cases and 30 controls) samples.
170 Genomic DNA was isolated from peripheral blood samples by miller's protocol of DNA isolation.
171 DNA was quantified by using a Nanodrop spectrophotometer (Thermo Scientific Corp., USA).

172

173

174

175

176 **Analysis of nucleotide variations in the BMP15 gene**

177 The nucleotide variations in the *BMP15* gene were analyzed in cases (n=28) and controls (n=30). In
178 the analysis of the *BMP15* gene, 2 exons (with reference to July 2009 assembly of ensemble.

179

180 Amplicons (amplified exons) were electrophoresed using 1.8 % agarose gel. Amplified PCR
181 products were purified using gel/PCR DNA fragments extraction kit (Geneaid Biotech Ltd., Sijhih
182 City Taiwan. Cat no DF100). Purified PCR products were sent for sequencing at MCLAB
183 (Molecular Cloning Laboratories) South San Francisco, CA 94080, U.S.A.
184 (<http://www.mclab.com/product.php?productid=19071>). DNA sequences were analyzed against
185 BMP15 reference sequence ENST00000252677.3 using ClustalW2 (multiple sequence alignment
186 program for DNA available at <http://www.ebi.ac.uk/Tools/clustalw2/index.html> provided by
187 European Molecular Biology Laboratory (EMBL) – European Bioinformatics Institute (EBI).

188

189

190

191

Statistical Analysis

192 The data has been expressed as mean \pm SD and/or median (minimum, maximum) as per the
193 statistical conventions. Associations were investigated by the chi-square test or fisher's exact test.
194 SPSS 11.5 (Texas, USA) was used for statistical analysis. Univariate and multivariable logistic
195 regression was done to see the unadjusted and adjusted odds ratio with 95%CI. All the p-values less
196 than 0.05 were taken as significant.

197

198

199

200

201

RESULTS

202 MOLECULAR ANALYSIS

203 By using sequencing analysis software (Chromas pro-2.4), it was observed that, in 3 cases,
204 polymorphism at rs3810682: g.50910775C>G Promoter region of exon -1 of the *BMP15* gene was
205 present. Of the 3 in one case, it was homozygous change while in 2 cases, the heterozygous change
206 was observed. (fig.2)

207

208 Out of 3 in one case, it was homozygous change. The frequency of the homozygous allele SNPs in
209 cases was 3.7%. In other 2 cases, the heterozygous change was observed. The frequency of the
210 heterozygous allele SNPs in cases was 7%. Besides cases, in one control heterozygous
211 polymorphism was also observed. The frequency of heterozygous allele SNPs in control was 3.3%
212 and frequency of the homozygous allele SNPs in control was 0%. (Table no. 2) All these changes
213 were present at the same location (Promoter region of exon -1 of the *BMP15* gene).

214

215

216 Fisher's exact test was used to analyze the frequency of SNP variant. It has been found the
217 prevalence of *BMP-15* SNP (rs3810682: g.50910775C>G) among cases was 10.7% and in controls
218 3.3 %. Although, P-value observed 0.344 (at 95% significance level), which was not significant but
219 prevalence was more in cases as compared to controls. (Table no. 3)

220

221

Discussion

222 The possible involvement of *BMP15* in POF pathogenesis was supported by evidence in animal
223 models.¹⁵ Di pasquale et.al, 2004 reported the first mutation of the *BMP15* gene in two sisters with
224 ovarian dysgenesis. They also described the significant association of heterozygous *BMP15* gene
225 variants with the POF phenotype in humans (seven of 166 patients: 4.2%; *P*- 0.003 vs. controls).
226 These findings are consistent with the critical role played by *BMP15* in human folliculogenesis.¹⁶

227

228 Fonesca et al., 2014, were taken an in-silico approach, which identified that the *PITX1*
229 (pituitary homeobox 1 protein) factor binds to a sequence located between -14 to -8 of the *BMP15*
230 promoter. It was shown that *PITX1* and *BMP15* are co-expressed in both human adult oocytes and in
231 adult mouse ovaries. Functional in-vitro experiments showed that both *BMP15* promoter constructs
232 (*BMP15*-prom-G and *BMP15*-prom-C) were activated by *PITX1*. A statistically significant 1.6 fold
233
234
235 increase in *BMP15* transcription activity conferred by the *BMP15*-prom-G construct was found. This
236 feature might lead to alterations in granulosa cell proliferation rate, which may contribute towards
237 POF molecular etiology.¹³

238

239 In the present study, we, therefore, decided to verify the prevalence of *BMP15* gene
240 alterations among the POF populations. It was observed that both heterozygous and homozygous
241 SNPs (*BMP15* GENE Promoter region: -9C>G rs3810682: g.50910775C>G) distribution in cases
242 and controls) were present in 3 cases among 28 cases and in one control was observed. The
243 prevalence was higher in cases as compared to controls. By using fisher exact t-test, we observed
244 that although prevalence was higher in cases but p-value was 0.34, which was not significant at 95%
245
246 CI. This might be due to small sample size. In present study also observed that heterozygous SNPs
247 were more than Homozygous SNPs. Out of 3 in one case, it was homozygous change. The frequency
248 of homozygous allele SNPs in cases was 3.7%. In other 2 cases, the heterozygous change was
249 observed. The frequency of heterozygous allele SNPs in cases was 7%. Besides cases, in one control
250 heterozygous polymorphism was also observed. The frequency of heterozygous allele SNPs in
251 control was 3.3% and frequency of homozygous allele SNPs in control was 0%. All these changes
252 were present at the same location (Promoter region of exon -1 of the *BMP15* gene). Two cases

253 presented with secondary amenorrhea and one with primary amenorrhea. So it suggesting that SNPs
254 associated with *BMP-15* gene cause both primary and secondary amenorrhea.

255

256

257

CONCLUSION

258

259 In previous literature, it has been observed that there is a strong correlation between mutation or
260 SNPs of *BMP-15* gene and premature ovarian failure as the *BMP-15* gene is a regulator of important
261 actions of granulosa cells of the ovary.

262

263 In the present study, it was observed that both heterozygous and homozygous SNPs were
264 present in 3 of 28 cases and in one control heterozygous SNPs was observed. The prevalence was
265 higher in cases as compared to controls. By using fisher exact t-test, we observed that although
266 prevalence was higher in cases but p-value was 0.34, which was not significant at 95% CI. This
267 insignificance was due to recruitment of few cases, who presented with idiopathic POF which have
268 normal (46, XX) karyotype. In present study also observed that heterozygous SNPs were more than
269 Homozygous SNPs. Two cases presented with secondary amenorrhea and one with primary

270

271 amenorrhea. So it suggesting that SNPs associated with *BMP-15* gene cause both primary and
272 secondary amenorrhea

273 Further study, needed with a large cohort of idiopathic cases of premature ovarian
274 failure, to determine the prevalence of allele frequency observed during the study and its genotype-
275 phenotype correlation among both the primary & secondary ovarian failure patients in Indian

276 population and expand mutation spectrum.

277

278 **DISCLOSURE:** conflict of interest- “None”

279

280 **BIBLIOGRAPHY**

281

282

283 1. Conway GS, Kaltsas G, Patel A, Davies MC, Jacobs HS. Characterization of idiopathic
284 premature ovarian failure. *Fertil Steril.* 1996; 64:337–41.

285

286 2. Goswami D, Conway GS. Premature ovarian failure. *Hum Reprod Update.* 2005 Jul-Aug;
287 11(4):391-410.

288

289 3. Coulam CB, Adamson SC, Annegers JF: Incidence of premature ovarian failure. *Obstet*
290 *Gynecol* 67:604-606, 1986.

291

292 4. Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, Shawker TH,
293 Merino MJ. Development of luteinized graafian follicles in patients with karyotypically normal
294 spontaneous premature ovarian failure. *J Clin Endocrinol Metab.* 1994 Nov; 79(5):1470-5.

295

296 5. Persani L, R. Rossetti, C. Cacciatore Genes involved in human premature ovarian failure J.
297 *Mol. Endocrinol*, 45 (2010), pp. 257–279

298

299 6. Timmreck LS, R.H. Reindollar Contemporary issues in primary amenorrhea *Obstet.*
300 *Gynecol. Clin. North Am*, 30 (2003), pp. 287–302

301

302 7. Kinch R, Plunkett E, Smout M, Carr D. Primary Ovarian Failure; A Clinicopathological
303 And Cytogenetic Study. *Am J Obstet Gynecol.* 1965 Mar 1; 91:630-44.

304

305 8. Kumar M, Pathak D, Venkatesh S, Kriplani A, Ammini AC, Dada R. Chromosomal
306 abnormalities & oxidative stress in women with premature ovarian failure (POF). *The Indian*
307 *Journal of Medical Research.* 2012; 135(1):92-97.

308

309 9. Pu D, Xing Y, Gao Y, Gu L, Wu J. Gene variation and premature ovarian failure: a meta-
310 analysis. *Eur J Obstet Gynecol Reprod Biol.* 2014 Nov; 182:226-37

311

312 10. Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. The bone morphogenetic
313 protein 15 gene is X-linked and expressed in oocytes. *Mol Endocrinol.* 1998 Dec; 12(12):1809-17.

314

315 11. Hanrahan JP, Gregan SM, Mulsant P, Mullen M, Davis GH, Powell R, Galloway SM.
316 Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with
317 both increased ovulation rate and sterility in Cambridge and Belclare sheep (*Ovis aries*). *Biol*
318 *Reprod.* 2004 Apr; 70(4):900-9

319

320 12. Persani L, R. Rossetti, E. Di Pasquale, C. Cacciatore, S. Fabre The fundamental role of
321 bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders.
322 *Hum. Reprod. Update,* 20 (2014), pp. 869–883

323

324 13. Fonseca DJ, Ortega-Recalde O, Esteban-Perez C, Moreno-Ortiz H, Patiño LC, Bermúdez
325 OM, Ortiz AM, Restrepo CM, Lucena E, Laissue P. BMP15 c.-9C>G promoter sequence variant

326 may contribute to the cause of non-syndromic premature ovarian failure. *Reprod Biomed Online*.
327 2014 Nov; 29(5):627-33.

328

329 14. Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, Guerra R, Kushner H, Schwartz S,
330 Sybert VP, Van Dyke DL, Ross JL. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1.
331 *Am J Hum Genet*. 1998 Dec; 63(6):1757-66.

332

333 15. Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL, Jokiranta TS,
334 McLaren RJ, Luiro K, Dodds KG, Montgomery GW, Beattie AE, Davis GH, Ritvos O. Mutations
335 in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a
336 dosage-sensitive manner. *Nat Genet*. 2000 Jul; 25(3):279-83.

337

338 16. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic Ovarian Failure Associated
339 with an Inherited Mutation of Human Bone Morphogenetic Protein-15 (BMP15) Gene. *American*
340 *Journal of Human Genetics*. 2004; 75(1):106-111.

341

342 17. McNatty KP, Galloway SM, Wilson T, Smith P, Hudson NL, O'Connell A, Bibby AH, Heath
343 DA, Davis GH, Hanrahan JP, Juengel JL. Physiological effects of major genes affecting ovulation
344 rate in sheep. *Genet Sel Evol*. 2005; 37 Suppl 1:S25-38.

345

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100

100
100


100
100

100
100


100

100

Reference



Patient homozygous change



medRxiv preprint doi: <https://doi.org/10.1101/2024.08.29.24151416>; this version posted August 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

Patient heterozygous change




Fig. 2: Chromatogram showing sequencing results

Designed primers: for 2 exons of *BMP15* gene.

Exon 1	Forward-GGA GCC AGG ATG CAG TTA TCT GC Reverse -CAG GGC AGT ATG GGG GCA TAA C
Exon 2	Forward-GGT TCT GGA ATA ACA AGG GAC Reverse-CTC TCC TCC AGT TTC CTG G

Table no. 1: Primers for Exon-1 & Exon-2 of *BMP15* gene

Allele	CASES		CONTROL		TOTAL	
	N	%	N	%	N	%
Heterozygous (C/G)	2	7%	1	3.3%	3	5.2%
Homozygous (G/G)	1	3.7%	0	0%	1	1.7%
Homozygous (Reference-Normal) (C/C)	25	89.3%	29	96.3%	54	93.1%
Total	28	%	30	100%	58	100%

Table no. 2: Allele frequency of SNPs among Cases & Controls

Group	<i>BMP15 reference gene</i> (CC-Wild type)	<i>BMP15 variant (CG/GG)HOMO/ HETEROZYGOUS VARIANT</i>	Total
Cases	25(89.3%)	3(10.7%)	28 (100%)
Controls	29(96.7%)	1(3.3%)	30 (100%)
Total	54(93.1%)	4(6.9%)	58(100%)

Table no. 3: *BMP15* GENE (Rs3810682: g.50910775C>G) SNPs distribution in cases and controls